Vir Biotechnology Inc. and GlaxoSmithKline plc revealed on Monday that the phase 2/3 study of their jointly developed coronavirus antibody treatment began last week.
VIR-7831 (or GSK4182136), which has been described by the companies as a "fully human" anti-coronavirus "monoclonal antibody," will be administered to 1,300 COVID-19 patients who are in early stages of the disease and are at high risk of hospitalization. The firms expect that the study's preliminary results emerge ahead of the end of 2020, with full results possibly appearing in the first quarter of next year. "Potentially early access to the antibody treatment" could be expected in the first half of 2021, the companies noted.
Vir Biotechnology's stock jumped 9.87% in premarket following the release of the statement.
